Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, Kamsteeg M, Giovannone B, Drylewicz J, van Amerongen CCA, Delemarre EM, Knol EF, van Wijk F, Nierkens S, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS.
Ariëns LFM, et al. Among authors: van der schaft j.
Allergy. 2020 Jan;75(1):116-126. doi: 10.1111/all.14080. Epub 2019 Oct 31.
Allergy. 2020.
PMID: 31593343